Trending
September 18, 2024
September 16, 2024
Sen-Jam Pharmaceutical, founded in 2017 and based in Huntington, New York, is co-led by Jackie Iversen, RPh MS, who serves as the Chief Clinical Officer. Jackie is a visionary pharmacist with expertise in pharmacokinetics and pain management. She is a leader in clinical research and pharmaceutical education, with ten scientific publications and a background as a Memorial Sloan Kettering Research fellow.
When discussing her background and the experiences that led to her founding Sen-Jam Pharmaceutical, Jackie Iversen shared that she started the company with a vision to improve pain management. During her research fellowship at Memorial Sloan Kettering, she noticed that the medical community often treated pain only after it occurred rather than preventing it. As a hospital pharmacist who loves science, she saw many patients suffering despite the available medications. This inspired her to create evidence-based solutions to proactively address pain and inflammation, aiming to improve patient outcomes and challenge the status quo.
The devastating impact of the opioid crisis, driven by unethical pharmaceutical practices favoring addictive drugs, served as inspiration for her to take action. Recognizing that earlier development of alternative pharmaceuticals could have mitigated the risk and devastation caused by widespread opioid addiction, she believed in the transformative potential of drug development to influence prescribing habits and policies through education. Sen-Jam is dedicated to creating non-opioid treatments for pain and inflammation, as well as exploring safer methods to modulate the immune system. Leveraging cutting-edge technologies like artificial intelligence and digital clinical trials, along with collaborative partnerships, Sen-Jam swiftly and affordably develops innovative products. This nimble approach enables them to provide superior solutions to patients in a timely manner, challenging larger pharmaceutical companies by targeting the same mechanisms of action with existing, safe drugs.
Sen-Jam embarked on its journey with an initial idea that has since grown into a valuable portfolio of over 60 patents. These patents offer crucial intellectual property protection, enabling the development of innovative therapeutics to address significant unmet needs. Through strategic partnerships with industry leaders like KVK-Tech, Duke University, People Science, and the National Institute of Drug Abuse, Sen-Jam aligns with partners who share its mission of making transformative therapeutics widely accessible. These milestones have played a pivotal role in propelling Sen-Jam’s growth and success.
Sen-Jam is dedicated to promoting healthy aging by safely regulating the immune system, which is essential for overall well-being. Their focus is on preventing inflammation before it harms tissues and causes illness. They develop wide-ranging anti-inflammatory products to shield the immune system from diverse forms of inflammation triggered by environmental factors like diet, stress, and substance abuse or diseases such as cardiometabolic disorders, autoimmune conditions, and cancer. By addressing inflammation early on, Sen-Jam aims to alter the trajectory of these conditions for a significant portion of the global population.
Safety and efficacy are of utmost importance to Sen-Jam. Their products are crafted from repurposed small molecules with extensive safety records spanning decades, providing a sturdy groundwork. Additionally, they uphold the “do no harm” principle and conduct thorough clinical testing, dedicated to employing an evidence-based approach across all their solutions.
Sen-Jam takes pride in its entire pipeline, with a special focus on SJP-002C. This product is in the final stages of its Phase 2 Clinical Trial, conducted in partnership with Duke University, renowned for its expertise in treating infectious diseases worldwide. SJP-002C introduces an anti-inflammatory element to the standard treatment for upper respiratory infections, aiming to decrease lung tissue damage over the long term as well as decreasing neuroinflammation in the brain that has more recently been associated with long hauler effects. The team eagerly anticipates the trial results, hoping they will showcase the substantial potential of their holistic platform approach, further bolstering future pipeline development.
Over the next five years, Sen-Jam has three key strategic objectives. Initially, they strive to secure funding for their endeavors from retail investors, exemplifying their commitment to “pharma for the people” through their Wefunder campaign ( wefunder.com/senjam ). Next, they aim to progress their assets through Phase 2 and Phase 3 clinical trials and seek FDA approval for them. Lastly, they endeavor to identify strategic partners who can aid in the sale and licensing of their assets, facilitating full commercialization potential in all available markets.
The pharmaceutical industry is primed for change, with dwindling trust, and healthcare is often perceived as reactive rather than proactive. Sen-Jam is determined to shift this paradigm by tackling inflammation, a silent threat, proactively preserving health. Their goal is to bridge the gap between the supplement market’s proactive mindset and the pharmaceutical industry’s evidence-based approach. By embracing cutting-edge science, utilizing AI, and collaborating with futurists and scientists, Sen-Jam aims to usher in a new era of personalized, proactive healthcare, empowering individuals to lead longer, healthier lives.
Sen-Jam is thrilled about its partnership with the National Institute of Drug Abuse (NIDA) to launch its opioid withdrawal product, SJP-005. NIDA sees potential in this broad-spectrum, non-opioid anti-inflammatory to revolutionize addiction treatment. Leveraging this partnership, which has previously brought numerous successful products to market, Sen-Jam anticipates accelerated development of their innovative solution, validating its scientific merit and, more importantly, saving lives and restoring dignity to millions.
Sen-Jam is collaborating with scientists to develop a wearable device to address the critical need for quantifying and monitoring inflammation. This device, similar to a glucose monitor for the metabolic system, will continuously measure immune system activity. By providing real-time data on immune function, this innovation will empower individuals to take proactive steps towards better health and longevity, promising an exciting advancement in healthcare technology.
“Sen-Jam Pharmaceutical’s visionary quest to redefine pain management and enhance longevity through groundbreaking inflammation treatments is nothing short of awe-inspiring.”
CEO/Co-Founder Jim Iversen Headshot
Chief Clinical Officer/Co-Founder Jackie Iversen Headshot
